Lack of efficacy of psychological and pharmacological treatments of disorders of eating behavior: neurobiological background

Francesca Brambilla, Federico Amianto, Riccardo Dalle Grave, Secondo Fassino, Francesca Brambilla, Federico Amianto, Riccardo Dalle Grave, Secondo Fassino

Abstract

Background: Treatments of eating disorders result too often in partial psychological and physical remission, chronicization, dropout, relapse and death, with no fully known explanations for this failure. In order to clarify this problem, we conducted three studies to identify the biochemical background of cognitive-behavioural psychotherapy (CBT), individual psychology brief psychotherapy (IBPP), and psychotherapy-pharmacotherapy with CBT + olanzapine in anorexics (AN) and bulimics (BN) by measuring the levels of plasma homovanillic acid (HVA) for dopamine secretion, plasma 3-methoxy-4-hydroxy-phenylglycol (MHPG) for noradrenalin secretion, and platelet [3H]-Paroxetin-binding Bmax and Kd for serotonin transporter function. The data were then compared with psychopathological and physical alterations.

Methods: Study 1 investigated the effects of 4 months of CBT on plasma HVA, MHPG and [3H]-Par-binding in 14 AN-restricted, 14 AN-bingeing/purging, and 22 BN inpatients. Study 2 investigated the effects of 4 months of IBPP on plasma HVA in 15 AN and 17 BN outpatients. Study 3 investigated the effect of 3 months of CBT + olanzapine (5 mg/day) in 30 AN outpatients. The data were analyzed using one-way ANOVA for repeated measures for the changes between basal and post-treatment biological and psychological parameters, two-way ANOVA for repeated measures for the differences in the psychobiological data in the 3 groups, Spearman's test for the correlations between basal and final changes in the psychological and biological scores.

Results: Study 1 revealed significant amelioration of the psychopathology in the AN and BN patients, no effects on HVA, MHPG or Paroxetin binding Kd, and a significant increase in Par-binding Bmax only in the BN patients. Study 2 revealed a significant effect of IBPP on psychopathology in the AN and BN patients, and a significant increase in HVA only in the BN patients. Study 3 revealed a significant positive effect of CBT + olanzapine therapy on the psychopathology and increased HVA values. No correlations were observed in the 3 groups between biological and psychological effects of the three treatments.

Conclusions: Our data advance suggestions on the mechanism of action of the three therapies; however, the lack of correlations between biochemical and psychological effects casts doubt on their significance. Clinical Trials.gov. Identifier NCT01990755 .

References

    1. NICE: Eating Disorders-Core Interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. In: NICE Clinical Guideline No. 9, National Institute for Clinical Excellence/Gaskell and the British Psychological Society, London/London; 2011.
    1. Wilson TJ, Fairburn GC. Treatment for Eating Disorder. In: Nathan PE, Gorman JM, editors. A Guide to Treatments that Work. New York: Oxford University Press; 2007.
    1. Fairburn CG, Cooper Z, O’Connor ME, Bohn K, Hawker DM, Wales JA, Palmer RL. Transdiagnostic Cognitive-Behavioral Therapy for patients with Eating Disorders: a two-site trial with 60-week follow-up. Am J Psychiatr. 2009;166(3):311–319. doi: 10.1176/appi.ajp.2008.08040608.
    1. Safer DL, Robinson AH, Jo B. Outcome from a randomized controlled trial of group therapy for Binge Eating disorder: comparing Dialectical Behavior Therapy adapted for Binge Eating to an Active Comparison group therapy. Behav Ther. 2010;41:106–120. doi: 10.1016/j.beth.2009.01.006.
    1. Aigner M, Treasure J, Kaye W, Kasper S, WFSBP Task Force On Eating Disorders World Federation Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders. World J Biol Psychiatr. 2011;12:400–443. doi: 10.3109/15622975.2011.602720.
    1. Kaye WH, Frank GK, McConaha C. Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacol. 1999;21:503–506. doi: 10.1016/S0893-133X(99)00053-6.
    1. Frank GK, Bailer UF, Henry SE, Drevets V, Meltzer CC, Price JC, Mathis CA Wagner A, Hoge J, Ziolko S, Barbarich-Marsteller N, Weissfeld L, Kaye WH. Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11-CL] raclopride. Biol Psychiatr. 2005;58:908–912. doi: 10.1016/j.biopsych.2005.05.003.
    1. Wagner A, Aizenstein H, Mazurkewicz L, Fudge J, Frank GK, Putnam K, Bailer UF, Fischer L, Kaye WH. Altered insula response to taste stimuli in individuals recovered from restricting-type Anorexia Nervosa. Neuropsychopharmacol. 2008;33:513–523. doi: 10.1038/sj.npp.1301443.
    1. Kaye WH, Ebert MH, Raleigh M, Lake R. Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch Gen Psychiatr. 1984;41:350–355. doi: 10.1001/archpsyc.1984.01790150040007.
    1. Kaye WH, Gwirtsman HE, George DT, Ebert H. 5HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatr. 1988;23:102–105. doi: 10.1016/0006-3223(88)90113-8.
    1. Kaye WH, Gwirtsman HE, George DT, Ebert H. Altered serotonin activity in anorexia nervosa after long-term weight recovery. Arch Gen Psychiatr. 1991;48:556–562. doi: 10.1001/archpsyc.1991.01810300068010.
    1. Kaye WH, Frank GK, Meltzer CC, Price JC, McKonaha CW, Crossan PJ, Klump KL, Rhodes L. Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. Am J Psychiatr. 2001;158:1152–1155. doi: 10.1176/appi.ajp.158.7.1152.
    1. Kaye WH, Barbarich NC, Putnam K, Gendall KA, Fernstrom J, Fernstrom M, McConaha CV, Kishore A. Anxiolitic effects of acute tryptophan depletion in anorexia nervosa. Int J Eat Dis. 2003;33:257–267. doi: 10.1002/eat.10135.
    1. Brambilla F, Bellodi L, Arancio C, Ronchi P, Limonta D. Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology. 2001;26:393–409. doi: 10.1016/S0306-4530(00)00062-7.
    1. Bailer UF, Price JC, Meltzer CC, Mathis C, Frank GK, Wissfeld L, McConaha CW, Henry SE, Brooks-Achenbach S, Barbarich NC, Kaye WH. Altered 5-HT2a receptor binding after recovery from bulimia-type anorexia nervosa: relationship to harm avoidance and drive for thinness. Neuropsychopharmacol. 2004;29:1143–1155. doi: 10.1038/sj.npp.1300430.
    1. Bailer UF, Bloss C, Frank G, Meltzer C, Mathis CA, Geyer MA, Wagner A, Becker CR, Schork NJ, Kaye WH. 5-HT1A receptor binding is increased after recoveryfrom bulimia nervosa compared to control women and is associated with behavioural inhibition in both groups. Int J Eat Dis. 2011;44:477–487. doi: 10.1002/eat.20843.
    1. Bailer UF, Frank GK, Price JC, Meltzer CC, Becker C, Mathis CA, Wagner A, Barbarich-Marsteller NC, Bloss CS, Putman K, Schork NJ, Gamst A, Kaye WH. Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa. Psychiatr Res. 2013;211:160–168. doi: 10.1016/j.pscychresns.2012.06.010.
    1. Fairburn CG, Harrison PJ. Eating Disorders. Lancet. 2003;361:407–416. doi: 10.1016/S0140-6736(03)12378-1.
    1. Dalle Grave R. A multiple-step cognitive behaviour therapy for eating disorders. Eat Dis Rev. 2005;13:372–382. doi: 10.1002/erv.664.
    1. Marazziti D. Pertugi G, Delitto J, Lenzi A, Maremmani I, Placidi GF, Cassano GB: High-affinity 3H-imiparmine binding sites: a possible state-dependent marker for major depression. Psychiatr Res. 1988;23:229–237. doi: 10.1016/0165-1781(88)90013-3.
    1. Sternberg DE, Heninger GR, Roth RH. Plasma homovanillic acid as an index of brain dopamine metabolism: Enhancement with debrisoquin. Life Sci. 1983;32:2447–2452. doi: 10.1016/0024-3205(83)90370-3.
    1. Glazer WM, Charney DS, Heninger GR. Noradrenergic function in schizophrenia. Arch Gen Psychiatr. 1987;44:898–904. doi: 10.1001/archpsyc.1987.01800220068010.
    1. Rausch J, Johnson ME, Li J, Hutcheson J, Carr BM, Corley KM, Gowan AB, Smith J: Serotonin transporter kinetics correlated between human platelets and brain synaptosomes.Psychopharmacol 2005, 180:391.398.
    1. Fassino S, Amianto F, Ferrero A. Brief Adlerian psychodynamic psychotherapy: theoretical Issues and process indicators. Panminerva Med. 2008;50:165–175.
    1. Gerhardt GA, Drebing CJ, Freedman R. Simultaneous determination of free homovanillic acid (HVA), 3-methoxy-4-hydroxyphenylglycol (MHPG) and vanyllilmandelic acid (VMA) in human plasma by HPLC coupled with dual electrode coulorimetric electrochemical detection. Anal Chem. 1986;58:2879–2883. doi: 10.1021/ac00126a067.
    1. Monteleone P, Brambilla F, Bortolotti F, LaRocca A, Maj M. Prolactin response to d-fenfluramine is blunted in people with anorexia nervosa. Brit J Psychiatr. 1998;172:418–442. doi: 10.1192/bjp.172.5.439.
    1. Favaro A, Caregaro L, Burina AB, Santonastaso P. Tryptophan levels, excessive exercise, and nutritional status in anorexia nervosa. Psychosom Med. 2000;65:535–538. doi: 10.1097/00006842-200007000-00012.
    1. Bruce KR, Steiger H, NG Ying Kin NMK, Israel M. Reduced platelet [3H]paroxetine binding in anorexia nervosa: relationship to eating symptoms and personality pathology. Psychiatr Res. 2006;142:225–232. doi: 10.1016/j.psychres.2005.08.007.
    1. Eckman A, Sundblad-Elverfors C, Landeén M, Eriksson T, Eriksson E. Low density and high affinity of platelet [3H]paroxetine-binding in women with bulimia nervosa. Psychiatr Res. 2006;142:219–233. doi: 10.1016/j.psychres.2006.02.012.
    1. Halmi KA, Dekirmeniijian H, Davis JM, Casper R, Goldberg S. Catecholamine metabolism in anorexia nervosa. Arch Gen Psychiatr. 1978;35:458–460. doi: 10.1001/archpsyc.1978.01770280068007.
    1. Jimerson DC, Lesem MD, Kaye WH, Brewerton TD. Symptom severity and neurotransmitter studies in bulimia. Psychopharmacol. 1988;96:124–129.
    1. Brambilla F, Bellodi L, Arancio C, Ronchi P, Limonta D. Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinol. 2001;26:393–409. doi: 10.1016/S0306-4530(00)00062-7.
    1. Castro Formieles J, Deaulofeu R, Baeza I, Casulà V, Saura B, Labaro L, Puig J, Toro J, Bernardo M. Psychopathological and nutritional correlates of plasma homovanillic acid in adolescent with anorexia nervosa. J Psychiatr Res. 2008;42:213–220. doi: 10.1016/j.jpsychires.2006.10.009.
    1. Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiol Behav. 2008;94:121–135. doi: 10.1016/j.physbeh.2007.11.037.
    1. Vandereiken W, Pierlot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 1982;66:445–450. doi: 10.1111/j.1600-0447.1982.tb04501.x.
    1. Vandereiken W: Neuroleptics in the short-term treatment of anorexia nervosa. A double- blind placebo-controlled study with sulpiride.Brit J Psychiatr 1984, 144:288–292.
    1. Cassano GB, Miniati M, Pini S, Rotondo A, Banti S, Borri C, Camilleri V, Mauri M. Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J S Six Eat Dis. 2003;33:172–177. doi: 10.1002/eat.10130.
    1. Mondraty N, Birmingham CL, Touiz S, Sundakov V, Chapman L, Beaumont P. Randomized controlled trial of olanzapine in the treatment of outpatients with bulimia nervosa. J Clin Psychopharmacol. 2005;13:72–75. doi: 10.1037/1064-1297.13.1.72.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する